Search results
Results from the WOW.Com Content Network
Cariprazine, sold under the brand name Vraylar among others, is an atypical antipsychotic developed by Gedeon Richter, [8] which is used in the treatment of schizophrenia and bipolar disorder. [9] It is also prescribed as an add-on treatment for bipolar depression [ 10 ] and major depressive disorder . [ 6 ]
Chronic constipation may be a sign of irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD); a gastroenterologist can recommend both lifestyle changes and medications to help.
Constipation is more concerning when there is weight loss or anemia, blood is present in the stool, there is a history of inflammatory bowel disease or colon cancer in a person's family, or it is of new onset in someone who is older. [12] Treatment of constipation depends on the underlying cause and the duration that it has been present. [4]
The signs and symptoms of colorectal cancer depend on the location of the tumor in the bowel, and whether it has spread elsewhere in the body ().The classic warning signs include: worsening constipation, blood in the stool, decrease in stool caliber (thickness), loss of appetite, loss of weight, and nausea or vomiting in someone over 50 years old. [15]
Functional constipation, also known as chronic idiopathic constipation (CIC), is defined by less than three bowel movements per week, hard stools, severe straining, the sensation of anorectal blockage, the feeling of incomplete evacuation, and the need for manual maneuvers during feces, without organic abnormalities.
A doctor shares whether this TikTok constipation hack really works and what you can try for relief instead. ... a couple of times a day,” and you will have a bowel movement — so the video ...
Methylnaltrexone (MNTX, brand name Relistor), used in form of methylnaltrexone bromide (INN, USAN, BAN), is a medication that acts as a peripherally acting μ-opioid receptor antagonist that acts to reverse some of the side effects of opioid drugs such as constipation without significantly affecting pain relief or precipitating withdrawals.
The drugmaker is banking on the treatment to help power growth as patents on its older cancer drug, Revlimid, and blood thinner Eliquis expire later this decade. William Blair analysts expect $2.5 ...